GALT Galectin Therapeutics
- 1.040
- -0.960-48.00%
- 1.020
- -0.020-1.92%
Galectin Therapeutics News
Galectin Therapeutics | 8-K: Current report
Galectin Therapeutics | ARS: Annual Report to Security Holders
Galectin Therapeutics | DEFA14A: Others
Galectin Therapeutics | DEF 14A: Definitive information statements
Galectin Therapeutics | 8-K: Current report
Galectin Therapeutics | 8-K: Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
Galectin Therapeutics | 10-Q: Q3 2024 Earnings Report
Galectin Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director ELDRED KARY
Galectin Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director FREEMAN KEVIN D
Galectin Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director FREEMAN KEVIN D
Galectin Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Galectin Therapeutics | 8-K: Current report
Galectin Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Zordani Richard A. Jr.
Galectin Therapeutics | 8-K: Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
Galectin Therapeutics | 10-Q: Q2 2024 Earnings Report
Galectin Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Jamil Khurram
Galectin Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Jamil Khurram
Galectin Therapeutics | 8-K: Current report
Galectin Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Director ELDRED KARY
Galectin Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director ELDRED KARY
No Data